Increased serum osteocalcin levels in patients with paraplegia
- PMID: 1630849
- DOI: 10.1038/sc.1992.56
Increased serum osteocalcin levels in patients with paraplegia
Abstract
Osteocalcin(OC) is a specific serum parameter of bone formation. Since bone metabolism disturbances, including osteoporosis, are seen in paraplegia, the serum levels of OC, midregional parathyroid hormone(mPTH), intact para-thyroid hormone (iPTH) and calcitonin (CT) serum levels were determined in 13 patients with paraplegia or tetraplegia and 15 control subjects by radioimmunoassay in a cross sectional study. In addition, the urinary hydroxyproline/creatine and the urinary calcium/creatinine ratio was determined. Serum OC levels were significantly increased in the patients with spinal cord injury (p less than 0.02), whereas serum levels of mPTH, iPTH and CT were not statistically different. The urinary hydroxyproline/creatinine ratio was significantly higher in the patients than in the controls (p less than 0.02), and the urinary calcium/creatinine ratio also tended to be higher in the patients. In a follow up study over 6 months after spinal cord injury, serum OC, serum iPTH, urinary hydroxyproline/creatinine ratio and the calcium/creatinine ratio were determined in 6 patients at monthly intervals. Hyperhydroxyprolinuria preceded the gradual increase of serum OC from normal to clearly elevated levels. Our data suggest that increased bone resorption in paraplegia is linked to an enhanced osteoblastic activity.
Similar articles
-
Bone metabolism, parathyroid hormone, and calcitonin in paraplegia.Calcif Tissue Int. 1979 Jul 3;27(3):199-204. doi: 10.1007/BF02441186. Calcif Tissue Int. 1979. PMID: 114280 No abstract available.
-
Decreased serum osteocalcin levels in patients with postmenopausal osteoporosis.Acta Med Austriaca. 1991;18(5):114-6. Acta Med Austriaca. 1991. PMID: 1796722
-
[Bone metabolism in primary hypothyroidism in the adult].Minerva Endocrinol. 1991 Jan-Mar;16(1):7-10. Minerva Endocrinol. 1991. PMID: 1944017 Italian.
-
Bone remodeling and calcium homeostasis in patients with spinal cord injury: a review.Metabolism. 2011 Dec;60(12):1655-63. doi: 10.1016/j.metabol.2011.04.005. Epub 2011 May 31. Metabolism. 2011. PMID: 21632079 Review.
-
Immobilization osteoporosis in paraplegia.J Am Paraplegia Soc. 1992 Jul;15(3):163-70. doi: 10.1080/01952307.1992.11735870. J Am Paraplegia Soc. 1992. PMID: 1500942 Review.
Cited by
-
Early treatment with zoledronic acid prevents bone loss at the hip following acute spinal cord injury.Osteoporos Int. 2011 Jan;22(1):271-9. doi: 10.1007/s00198-010-1221-6. Epub 2010 Apr 1. Osteoporos Int. 2011. PMID: 20358358 Clinical Trial.
-
Bone loss and muscle atrophy in spinal cord injury: epidemiology, fracture prediction, and rehabilitation strategies.J Spinal Cord Med. 2006;29(5):489-500. doi: 10.1080/10790268.2006.11753898. J Spinal Cord Med. 2006. PMID: 17274487 Free PMC article. Review.
-
Effect of a convenient single 90-mg pamidronate dose on biochemical markers of bone metabolism in patients with acute spinal cord injury.J Spinal Cord Med. 2006;29(4):406-12. doi: 10.1080/10790268.2006.11753890. J Spinal Cord Med. 2006. PMID: 17044392 Free PMC article.
-
International spinal cord injury endocrine and metabolic extended data set.Spinal Cord. 2017 May;55(5):466-477. doi: 10.1038/sc.2016.164. Epub 2017 Mar 21. Spinal Cord. 2017. PMID: 28322240
-
Treatment with resveratrol attenuates sublesional bone loss in spinal cord-injured rats.Br J Pharmacol. 2013 Oct;170(4):796-806. doi: 10.1111/bph.12301. Br J Pharmacol. 2013. PMID: 23848300 Free PMC article.